Bio-Rad Laboratories (BIO) Cash & Current Investments (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Cash & Current Investments data on file, last reported at $1.6 billion in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 5.76% year-over-year to $1.6 billion in Q1 2026; TTM through Mar 2026 was $1.6 billion, a 5.76% decrease from a year earlier, with the FY2025 full-year figure at $1.5 billion, down 7.44% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $1.6 billion, up from $1.5 billion in the prior quarter.
• Over the last five years, Cash & Current Investments for BIO reached as high as $2.0 billion in Q2 2022 and fell as low as $412.5 million in Q2 2024.
• Historically, Cash & Current Investments has averaged $1.4 billion across 5 years, with a median of $1.6 billion in 2023.
• Across the five-year window, Cash & Current Investments slumped 76.06% in 2024 and jumped 278.34% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $1.8 billion in 2022, then dropped by 10.25% to $1.6 billion in 2023, then increased by 3.57% to $1.7 billion in 2024, then slipped by 7.44% to $1.5 billion in 2025, then gained by 1.56% to $1.6 billion in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $1.6 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.